IRCCS Azienda Ospedaliero-Universitaria di Bologna
Quick facts
Marketed products
- Metarapone · Other
- Placebo + Tiotropium · Respiratory / Pulmonology
Tiotropium is a long-acting anticholinergic bronchodilator that blocks muscarinic receptors in airway smooth muscle to produce sustained bronchodilation. - Salbutamol + Tiotropium · Respiratory/Pulmonology
Salbutamol is a short-acting beta-2 agonist that rapidly opens airways, while tiotropium is a long-acting anticholinergic that provides sustained bronchodilation for chronic airway obstruction. - Sequential therapy
Sequential therapy refers to a treatment approach that administers multiple therapeutic agents in a planned sequence rather than simultaneously, optimizing efficacy and tolerability. - Standardized antihypertensive therapy · Cardiovascular
Standardized antihypertensive therapy reduces blood pressure through one or more established pharmacological classes of antihypertensive agents.
Phase 3 pipeline
- Atezolizumab & Bevacizumab · Oncology
Atezolizumab blocks PD-L1 to restore anti-tumor immunity, while bevacizumab inhibits VEGF to reduce tumor angiogenesis, together enhancing immune-mediated tumor control. - LMWH parnaparin subcutaneously · Cardiovascular
Parnaparin is a low-molecular-weight heparin (LMWH) that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- IRCCS Azienda Ospedaliero-Universitaria di Bologna portfolio CI brief
- IRCCS Azienda Ospedaliero-Universitaria di Bologna pipeline updates RSS
Frequently asked questions about IRCCS Azienda Ospedaliero-Universitaria di Bologna
What are IRCCS Azienda Ospedaliero-Universitaria di Bologna's marketed drugs?
Top marketed products include Metarapone, Placebo + Tiotropium, Salbutamol + Tiotropium, Sequential therapy, Standardized antihypertensive therapy.
What is IRCCS Azienda Ospedaliero-Universitaria di Bologna's pipeline?
IRCCS Azienda Ospedaliero-Universitaria di Bologna has 2 drugs in Phase 3, 1 in Phase 2, 0 in Phase 1. Late-stage candidates include Atezolizumab & Bevacizumab, LMWH parnaparin subcutaneously.
Related
- Metarapone · Other
- Placebo + Tiotropium · Respiratory / Pulmonology
- Salbutamol + Tiotropium · Respiratory/Pulmonology
- Sequential therapy
- Standardized antihypertensive therapy · Cardiovascular
- Sector hub: All tracked pharma companies